COPD

Treatment

100

Which inhaler therapy is recommended for Mmrc <2 and CAT <10 with no exacerbation?

A bronchodilator 

200

Nebulized PDE inhibitor approved for persistent dysnea despite dual bronchodilator therapy

Ensifentrine 

300

What eosinophil count do we initiate ICS

300

400

Lung volume reduction surgery is beneficial specifically for which group of patients?

Upper lobe dependent emphysema and low exercise capacity 

500

What phenotype of patients on high eosinophil count on triple inhaler therapy benefit from Dupilimumab  ?

Chronic bronchitis phenotype 

Landmark trials

100

Oxygne trial mortalist 15h vs 24h

Redox trial

200

 

Indacaterol–glycopyrronium outperformed salmeterol–fluticasone in reducing exacerbations. 

Hint: Acronym is something that burns.

FLAME trial

300

One of the landmark trial to establish ICS increase risk of pneumonia

TORCH Trial

400

 

Oxygen therapy trial in the 1980s showed survival benefit in severe resting hypoxemia.

NOTT trial

500

High dose ICS vs low dose ICS in triple inhaler therapy did not 

ETHOS trial

Misc.

100

    patient with severe COPD has a resting PaO₂ of 58 mmHg on room air, a hematocrit of 57%, and no significant exertional desaturation. What evidence-based intervention has been shown to improve survival in this patient?

oxygen therapy 

200

 

This anti–IL-5 monoclonal antibody, used in asthma, failed to significantly reduce exacerbations in most COPD patients but showed  benefit in those with high eosinophils.

Mepolizumab

300

physiologic measurement of gas trapping is commonly required to be at least 150–175% predicted in pivotal EBV trials.

RV

400

This physiologic finding must be absent between the target and adjacent lobes for effective endobronchial valve treatment.

Collateral ventilation

500

After a COPD exacerbation requiring hospitalization, pulmonary rehabilitation is generally encouraged within this approximate timeframe once clinically stable.

90 days